Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.

摘要: SummaryTo compare the effects of rosiglitazone and pioglitazone on patient lipid levels in a clinical practice setting, we retrospectively examined charts 20 patients our practice. The had been treated for type 2 diabetes 3 or more months with (4 mg b.i.d.) followed immediately by months' treatment (45 mg once daily). Glycaemic control was excellent essentially equivalent during two treatments. At baseline, mean HbA1c level 7.6%; it dropped to 6.6% 6.3% treatment, respectively. Lipid levels, however, differed Triglyceride rose 13% but fell 14% below baseline therapy - 24% reduction overall (p = 0.02). Rosiglitazone associated significant increase low-densitylipoprotein cholesterol (LDL-C) (35%, p < 0.001 vs. baseline) total (22%, p < ...